Phase I Study of Oral beta-Glucan and Intravenous Rituximab Among Children and Adolescents With Relapsed CD20-Positive Lymphoma or Leukemia, or Post-Transplant Lymphoproliferative Disease
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Beta glucan (Primary) ; Rituximab
- Indications B-cell lymphoma; Hodgkin's disease; Post-transplant lymphoproliferative disorder; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 19 Mar 2013 Biomarkers information updated
- 18 Mar 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Dec 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.